In hypothetical situations, physicians chose intensive treatment more often if BP and mobility metrics were available.

While the strategies didn’t lower NT-proBNP after PCI in acute MI patients, they may suggest a way forward for intervening early.

The study should be the first of many helping to understand the negative CV effects of the drug in an illicit setting, say authors.

There was a consensus that more data are needed to answer this question, with discussions about what such a trial would look like.

Operative mortality fell over time, but there was a concerning uptick in recent years attributed to low-volume sites.

PE or PEERLESS, the choice of therapy was shifting, influenced by patient factors and institutional protocols.

Outcomes and expenses were similar with transplant and elective LVAD, but urgent LVAD after ECMO fared much worse.

The study emphasizes the importance of vigilance with diet and exercise, among other things, to reduce CV risk in type 2 diabetes.

Amid late-breaking coronary, structural, and endovascular trials will be a keynote from President Biden, and more.

Patients already had high NT-proBNP levels at baseline, though, raising questions about the quality of GDMT, Nancy Sweitzer ...

Even as BAT expands beyond trial criteria, patients see gains in LVEF, symptoms, and more. A survival impact remains unclear.